Neurofibromatosis type 1.

Area of Science:

• Genetics
• Oncology
• Neurology

Background:

• Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder resulting from NF1 gene mutations.
• It is characterized by café-au-lait macules, skinfold freckling, Lisch nodules, and dermal neurofibromas.
• Affected individuals may also develop skeletal abnormalities, brain and peripheral nerve tumors, and neurodevelopmental issues impacting quality of life.

Purpose of the Study:

• To review the current understanding of neurofibromatosis type 1 pathophysiology.
• To discuss advancements in preclinical models and emerging targeted therapies.
• To highlight the importance of early detection and multidisciplinary management for improving patient outcomes.

Main Methods:

• Review of scientific literature on NF1 genetics, clinical manifestations, and therapeutic strategies.
• Analysis of preclinical models for understanding disease mechanisms.
• Synthesis of information on current management and emerging interventions.

Main Results:

• NF1 is caused by germline mutations in the NF1 tumor suppressor gene.
• Preclinical models have advanced the understanding of NF1 pathophysiology.
• Targeted therapies and improved management strategies are becoming available.

Conclusions:

• Effective management of NF1 requires early detection and risk assessment.
• Biologically targeted therapies and medical/behavioral interventions are crucial for improving quality of life.
• A collaborative, interdisciplinary approach is essential for addressing the complexities of NF1 and developing future treatments.